$3.50
0.14% today
NYSE, Feb 28, 05:23 pm CET
ISIN
US68218J1034
Symbol
OABI
Sector
Industry

OmniAb Stock price

$3.50
+0.13 3.86% 1M
-0.81 18.79% 6M
-0.04 1.13% YTD
-2.83 44.71% 1Y
-5.29 60.18% 3Y
-5.29 60.18% 5Y
-5.29 60.18% 10Y
NYSE, Closing price Thu, Feb 27 2025
-0.02 0.57%
ISIN
US68218J1034
Symbol
OABI
Sector
Industry

Key metrics

Market capitalization $423.55m
Enterprise Value $388.01m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 19.01
P/S ratio (TTM) P/S ratio 20.75
P/B ratio (TTM) P/B ratio 1.44
Revenue growth (TTM) Revenue growth -68.45%
Revenue (TTM) Revenue $20.41m
EBIT (operating result TTM) EBIT $-82.21m
Free Cash Flow (TTM) Free Cash Flow $-46.85m
Cash position $59.38m
EPS (TTM) EPS $-0.62
P/E forward negative
P/S forward 16.45
EV/Sales forward 15.07
Short interest 7.72%
Show more

Is OmniAb a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

OmniAb Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a OmniAb forecast:

8x Buy
100%

Analyst Opinions

8 Analysts have issued a OmniAb forecast:

Buy
100%

Financial data from OmniAb

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
20 20
68% 68%
100%
- Direct Costs 21 21
21% 21%
102%
-0.50 -0.50
101% 101%
-2%
- Selling and Administrative Expenses 4.23 4.23
71% 71%
21%
- Research and Development Expense 57 57
3% 3%
277%
-61 -61
182% 182%
-300%
- Depreciation and Amortization 21 21
21% 21%
102%
EBIT (Operating Income) EBIT -82 -82
110% 110%
-403%
Net Profit -63 -63
112% 112%
-309%

In millions USD.

Don't miss a Thing! We will send you all news about OmniAb directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

OmniAb Stock News

Neutral
Business Wire
4 days ago
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three and 12 months ended December 31, 2024 after the close of the U.S. financial markets on Tuesday, March 18, 2025 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What:   OmniAb conference call to discuss fourth quart...
Neutral
Business Wire
25 days ago
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in two investor conferences during the month of March. TD Cowen 45th Annual Health Care Conference, March 3-5 at the Boston Marriott Copley Place. Management will be presenting a corporate overview on Tuesday, March 4th at 2:30 p.m. Eastern time and will be holding one-on-one m...
Neutral
PRNewsWire
28 days ago
NEW YORK , Jan. 31, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of OmniAb, Inc. (NASDAQ: OABI) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
More OmniAb News

Company Profile

OmniAb, Inc. operates as a drug discovery company. It focuses on developing human monoclonal and bispecific therapeutic antibodies. Its platform includes the biological intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse. The company was founded on December 14, 2015 and is headquartered in Emeryville, CA.

Head office United States
CEO Matthew Foehr
Employees 106
Founded 2015
Website www.omniab.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today